Company Filing History:
Years Active: 2019-2021
Title: Innovations of Anna Gardberg in BTK Inhibitors
Introduction
Anna Gardberg is an accomplished inventor based in Arlington, MA (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as inhibitors for Bruton's tyrosine kinase (BTK). With a total of 3 patents to her name, her work is paving the way for new therapeutic options.
Latest Patents
Anna's latest patents include innovative compounds that have shown promise as BTK inhibitors. One of her notable inventions is titled "Heteroaryl compounds as BTK inhibitors and uses thereof - Imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof are useful as BTK inhibitors." Another significant patent is "Heteroaryl compounds as BTK inhibitors and uses thereof - The present invention relates to pyridine, pyrimidine, pyrazine, and pyridazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors." These patents highlight her expertise in creating effective pharmaceutical compositions.
Career Highlights
Anna Gardberg is currently employed at Merck Patent GmbH, where she continues to innovate and contribute to the field of drug development. Her work at Merck has allowed her to collaborate with leading experts in the industry, further enhancing her research and development capabilities.
Collaborations
Some of Anna's notable coworkers include Hui Qiu and Richard Dana Caldwell. Their collaborative efforts have been instrumental in advancing the research and applications of BTK inhibitors.
Conclusion
Anna Gardberg's contributions to the field of pharmaceuticals, particularly in the development of BTK inhibitors, demonstrate her innovative spirit and dedication to improving healthcare. Her patents and collaborations reflect her commitment to advancing medical science.